Product Description
Organon is developing OG-6219, a 17beta-HSD1 Inhibitor to treat patients with endometriosis. (Sourced from: https://clinicaltrials.gov/ct2/show/NCT05560646)
Mechanisms of Action: 17beta-HSD1 Inhibitor
Novel Mechanism: Yes
Modality: Small Molecule
Route of Administration: Oral
FDA Designation: *
Approval Status: Not Approved
Approved Countries: None
Approved Indications: None
Company: Merck
Company Location: Eastern America
Company Founding Year: 1668
Additional Commercial Interests: None
Clinical Description
Countries in Clinic: Belgium, Bulgaria, Czech Republic, France, Germany, Hungary, Italy, Latvia, Poland, Sweden, United States
Active Clinical Trial Count: 2
Recent & Upcoming Milestones
Highest Development Phases
Phase 2: Endometriosis
Trial ID |
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
Latest Trial Update Date |
Data Updated |
|---|---|---|---|---|---|---|---|---|
NCT05560646 |
ELENA | P2 |
Completed |
Endometriosis |
2025-05-28 |
2025-05-31 |
Patient Enrollment|Primary Completion Date|Primary Endpoints|Study Completion Date|Treatments|Trial Status |
|
2022-501310-57-00 |
OG-6219-P001 | P2 |
Active, not recruiting |
Endometriosis |
2024-12-20 |
2025-05-02 |
Recent News Events
Date |
Type |
Title |
|---|---|---|
|
07/02/2025 |
News Article |
Organon Provides Update on Phase 2 ELENA Proof-of-Concept Study Evaluating OG-6219 in Patients with Endometriosis-Related Pain |
|
09/26/2023 |
News Article |
Endometriosis Pipeline, Clinical Trials Assessment, and FDA Approvals 2023 (Updated) |
|
11/03/2022 |
News Article |
Organon Reports Results for the Third Quarter Ended September 30, 2022 |
|
12/13/2021 |
News Article |
Organon Completes Acquisition of Forendo Pharma |